Intake of coffee, caffeine and other methylxanthines and risk of Type i vs Type II endometrial cancer

S. Uccella, A. Mariani, A. H. Wang, R. A. Vierkant, W. A. Cliby, K. Robien, K. E. Anderson, J. R. Cerhan

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

Background:Coffee and other sources of methylxanthines and risk of Type I vs Type II endometrial cancer (EC) have not been evaluated previously.Methods: Prospective cohort of 23 356 postmenopausal women with 471 Type I and 71 Type II EC cases.Results:Type I EC was statistically significantly associated with caffeinated (relative risk (RR)=0.65 for 4+ cups per day vs ≤1 cup per month: 95% confidence interval (CI): 0.47-0.89) but not decaffeinated (RR=0.76; 95% CI: 0.50-1.15) coffee intake; there were no associations with tea, cola or chocolate, or for Type II EC. The inverse association with caffeinated coffee intake was specific to women with a body mass index 30+ kg m-2 (RR=0.56; 95% CI: 0.36-0.89).Conclusion:Coffee may protect against Type I EC in obese postmenopausal women.

Original languageEnglish (US)
Pages (from-to)1908-1913
Number of pages6
JournalBritish journal of cancer
Volume109
Issue number7
DOIs
StatePublished - Oct 1 2013

Keywords

  • caffeine
  • coffee
  • cola
  • decaffeinated coffee
  • endometrial cancer
  • methylxanthines
  • tea

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Intake of coffee, caffeine and other methylxanthines and risk of Type i vs Type II endometrial cancer'. Together they form a unique fingerprint.

  • Cite this